NEW YORK (Reuters) - U.S. prosecutors brought insider trading charges against the founder and former chief executive of Auspex Pharmaceuticals Inc, accusing him of providing illegal tips to friends and family as Teva Pharmaceutical Industries Ltd (TEVA.TA) prepared to buy his company in a $3.5 billion transaction.
PureTech is repositioning an antifibrotic drug for use in the treatment of long-term lung dysfunction associated with COVID-19. The Boston-based biotech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.